Clinical Trial

Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated May 10, 2024 (before its estimated September 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a multicenter II study to compare KN026 and KN046 versus Oxaliplatin, Capecitabine combined KN026 and KN046 in patients with HER2-positive locally advanced resectable gastric cancer or gastroesophageal junction adenocarcinoma.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-09-03.
Status change: Not Yet Recruiting → Recruiting 2024-05-09
Trial Details
NCT Number NCT06023758
Lead Sponsor Peking University
Conditions HER2-positive Locally Advanced Resectable Gastric Cancer
Enrollment 18 participants
Start Date 2023-09-22
Primary Completion 2025-09-01 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-05-10